Scotiabank lifts gold price forecast and upgrades Newmont, Barrick
MBX Biosciences, Inc. (MBX:MBX) President and CEO Hawryluk P. Kent reported purchasing 20,000 shares of common stock on October 20, 2025. The $636.3 million market cap company has seen its stock surge 73% over the past six months, with analysts maintaining a Strong Buy consensus. According to InvestingPro analysis, the company currently trades above its Fair Value. The shares were bought at a weighted average price ranging from $13.60 to $13.6399, resulting in a total transaction value of $272790.
Following the transaction, Hawryluk P. Kent directly holds 481397 shares of MBX Biosciences , Inc. common stock. The purchase was made indirectly through a trust.
In other recent news, MBX Biosciences has been in the spotlight following various significant developments. The company announced the pricing of its upsized public offering, setting 11,108,055 shares at $18.00 each, which is projected to generate approximately $199.9 million in gross proceeds. This move comes amidst positive Phase 2 trial results for their drug canvuparatide, which demonstrated a 79% response rate for treating hypoparathyroidism. Mizuho has responded to these results by raising its price target for MBX Biosciences from $38 to $56, maintaining an Outperform rating. Meanwhile, Oppenheimer reiterated an Outperform rating with an $80 price target, despite a 30% drop in the stock since the Phase 2 data announcement. Truist Securities initiated coverage with a Buy rating and a $50 price target, emphasizing the potential of canvuparatide as a best-in-class treatment. Citizens also reiterated a Market Outperform rating with a $61 price target, noting the positive reception of canvuparatide at a recent medical meeting. These developments highlight the ongoing interest and varied perspectives among analysts regarding MBX Biosciences’ future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.